Subsequent work showed that the T790M mutation is the most common form of acquired resistance to EGFR‐TKIs in patients with sensitizing mutations of EGFR.36 This tumor line also represented “an experiment of nature” because the line was generated (and contained the T790M mutation) before EGFR TKIs were deployed in the clinic indicating the mutation arose without drug selection. This evidence concerns the gene EGFR and neoplasm.